Home/ADMA Biologics/Adam S. Grossman

AS

Adam S. Grossman

President, Chief Executive Officer and Director

Therapeutic Areas

Primary Immunodeficiency Infectious Diseases Secondary Immunodeficiency

ADMA Biologics Pipeline

Drug	Indication	Phase
ASCENIV	Primary Immunodeficiency Diseases (PIDD)	Marketed
BIVIGAM	Primary Humoral Immunodeficiency	Marketed
Nabi-HB	Hepatitis B Post-Exposure Prophylaxis	Marketed
IVIG Portfolio Expansion	Secondary Immunodeficiency	Lifecycle Management

Leadership Team at ADMA Biologics

Bryan M. Reasons

Chief Financial Officer

Chairman of the Board

Chief Medical Officer

Michele L. Willkommen

Chief Operations Officer

View full ADMA Biologics profile